Novartis

Risk With the Fix?

Two research teams warn that CRISPR-based gene editing could boost cancer risk by affecting p53 function, according to Stat News.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The test is intended to detect FLT3 mutations in order to select patients for treatment with Novartis' Rydapt, and has also been approved by the US FDA.

Pages

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.